A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer
Active, not recruiting · Phase 3 · NCT06939595
Conditions: Non Squamous Non Small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $490
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 225
About the trial
- Sponsor
- Celltrion
- Tested
- CT-P51 (drug), EU-approved Keytruda (drug)
- Dates
- Started 2025-01-30; completion 2028-07
- Results posted
- Not yet
The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.
From ClinicalTrials.gov, last updated 2026-07-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Celltrion, Inc. reported $490 in research payments for this study in 2025 (1 payments).
Products named: Ct-P51
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $490
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.